Madagascar vs Senegal: HIV/AIDS deaths averted by antiretroviral therapy
Madagascar
2,165 deaths
in 2024
Senegal
2,002 deaths
in 2024
Madagascar rank
55th
Senegal rank
57th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Madagascar
- Senegal
How they compare
Madagascar currently reports 2,165 deaths against 2,002 deaths in Senegal, a difference of 163 deaths.
That makes Madagascar's figure about 1.1 times Senegal's.
The two have swapped places 3 times across 35 shared years of data; in 1990 it was Senegal ahead.
Madagascar ranks 55th and Senegal ranks 57th of 157 countries.
Senegal has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Madagascar | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 14.82 deaths | 481.41 deaths | 466.59 deaths | Senegal |
| 2010s | 196.24 deaths | 1,757 deaths | 1,561 deaths | Senegal |
| 2020s | 1,309 deaths | 1,992 deaths | 682.93 deaths | Senegal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Madagascar or Senegal?
- Madagascar, at 2,165 deaths against 2,002 deaths in Senegal as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Madagascar and Senegal?
- 163 deaths, with Madagascar ahead.
- How many years of comparable data are there for Madagascar and Senegal?
- 35 years are reported by both, from 1990 to 2024.
- How do Madagascar and Senegal rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Madagascar ranks 55th and Senegal ranks 57th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.